Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Organon: It's Darkest Before The Dawn
02:52am, Thursday, 30'th Nov 2023
Organon is a global healthcare company focused on women's health, with a diverse portfolio of prescription therapies and medical devices. OGN stock has been on a downward trend due to declining sales
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
09:53am, Tuesday, 21'st Nov 2023
It has been over two years since Organon spun off from Merck. Lack of growth and deteriorating financials haven't given investors much of a reason to be bullish thus far.
Organon & Co (OGN) Q3 2023 Earnings Call Transcript
12:21pm, Thursday, 02'nd Nov 2023
Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D C
Organon: The Federal Reserve Black Swan (Rating Upgrade)
11:45am, Wednesday, 04'th Oct 2023
The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close look at the company's debt and how I think the sit
6% Yield And Significantly Undervalued: A Closer Look At Organon
02:23am, Sunday, 10'th Sep 2023
Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for income-oriented investors. The company has a stabl
S&P Gains and Losses Today: Bank Stocks Tumble on Moody's Downgrade
05:30pm, Tuesday, 08'th Aug 2023
The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.
Organon & Co (OGN) Q2 2023 Earnings Call Transcript
12:18pm, Tuesday, 08'th Aug 2023
Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Con
Organon results beat estimates on demand for women heath products, biosimilars
10:47am, Tuesday, 08'th Aug 2023
Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs, sending the healthcare firm's shares up about
Organon: Big Dividend And Upside Potential
08:05am, Monday, 17'th Jul 2023
Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, th
Final Trades: SLB, Organon, IQVIA & more
01:45pm, Friday, 14'th Jul 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.
06:45am, Wednesday, 05'th Jul 2023
Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s ABBV, +0.21% rh
3 S&P 500 Stocks to Own for the Next 50 Years
11:32am, Tuesday, 04'th Jul 2023
Survivorship bias is one of the biggest issues when selecting buy and hold stocks to own for the next 50 years. What is survivorship bias?
Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount
08:04am, Saturday, 01'st Jul 2023
Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while two other drugmakers entered t
Organon, Samsung Bioepis launch copycat for athritis drug Humira at 85% discount
06:38am, Saturday, 01'st Jul 2023
Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered the
Organon & Co (OGN) Q1 2023 Earnings Call Transcript
11:04am, Thursday, 04'th May 2023
Organon & Co. (NYSE:OGN ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Conference Call Participants Uniden
